Overview
The ICMR participated in the national programme विज्ञान–Tech on the occasion of National Technology Day 2026. The event, held at the BRIC‑National Institute of Immunology, New Delhi, was coordinated by the Principal Scientific Adviser and the Department of Biotechnology, reflecting a whole‑of‑government approach.
Key Developments
- Six high‑impact indigenous technologies were displayed, including Covaxin, a COVID‑Kavach ELISA kit, a CRISPR‑Cas‑based TB detection system, a Nipah point‑of‑care assay, a dengue ELISA kit, and a biolarvicide for mosquito control.
- A compendium of 25 promising technologies from various ICMR institutes was released, covering diagnostics, medical devices, digital health, disease surveillance and translational research.
- Three ICMR‑developed technologies were licensed to industry under the Medical Innovations Patent Mitra initiative:
- Cost‑effective PSP94 ELISA for prostate biopsy decisions – licensed to Krishgen Labs Pvt. Ltd.
- Factor VIII inhibitor/coagulation disorder point‑of‑care diagnostic – licensed to Meril Life Sciences
- Single‑tube multiplex real‑time RT‑PCR for dengue, chikungunya and Zika – licensed to Vanguard Life Sciences
Important Facts
The technology transfer session was part of a broader MoU exchange that showcased innovations from autonomous institutes of 14 scientific ministries. The licensing agreements aim to protect publicly funded inventions while enabling rapid commercialisation, aligning with the Make in Bharat vision.
Exam Relevance
For GS‑3 (Science & Technology) aspirants, the event illustrates how India leverages public‑private partnerships to translate research into market‑ready health solutions. It underscores the role of institutions like ICMR in addressing national health priorities, the importance of intellectual‑property frameworks such as the Medical Innovations Patent Mitra, and the policy thrust of self‑reliant healthcare ecosystems under the Viksit Bharat agenda.
Way Forward
To sustain momentum, the government should:
- Strengthen IP support for academic innovators and streamline licensing processes.
- Encourage scale‑up of licensed products through incentives for domestic manufacturing.
- Integrate these indigenous technologies into national health programmes such as the Ayushman Bharat scheme.
- Expand the विज्ञान–Tech platform to include more private sector participation and cross‑border collaborations.
These steps will deepen the innovation ecosystem, improve health security, and reinforce India’s position as a global hub for affordable medical technologies.